Dr. Abdulmohsen H. Alrohaimi is a distinguished academic, scientist, and leader whose career reflects a remarkable blend of innovation, dedication, and impactful contributions to science and education. Currently serving as an Associate Professor at the College of Pharmacy, Shaqra University, he has consistently played a pivotal role in advancing pharmaceutical education and healthcare in Saudi Arabia, aligning his efforts with the ambitious objectives of Vision 2030.
Dr. Alrohaimi’s academic journey is marked by exceptional achievements. He earned a PhD in Pharmacology and Experimental Therapeutics (Pharmacogenetics) from Tufts University in Boston, USA, in 2005. His extensive educational foundation also includes a Master’s degree in Periodontology from Tufts University (2002) and a Bachelor’s degree in Dental Surgery from King Saud University, Riyadh (1998). These academic milestones laid the groundwork for his multidisciplinary approach, enabling him to integrate fields such as nanomedicine, biotechnology, and pharmacogenetics into his research.
As a trailblazer in clinical trials infrastructure, Dr. Alrohaimi’s tenure as Executive Director at the Saudi Food and Drug Authority (SFDA) was transformative. He spearheaded the development of the Kingdom’s clinical trial framework, ensuring Saudi Arabia's active participation in global drug development and regulation. Additionally, he launched nationwide community awareness initiatives, fostering public understanding of drug safety and healthcare innovation.
Dr. Alrohaimi has held several key leadership roles at Shaqra University. As Dean of the College of Pharmacy, his leadership led to the PharmD program gaining recognition from MCPHS University, Boston. His administrative acumen extends beyond academia, having served as Vice Rector for Academic Affairs and General Supervisor of the Vision 2030 Office at Shaqra University. These roles underscore his commitment to bridging the gap between academic research and national development goals.
An accomplished author and researcher, Dr. Alrohaimi has published extensively in high-impact journals, focusing on areas such as stem cell techniques, nanomedicine-based drug delivery, and pharmacogenetics. His work has been showcased at numerous international conferences, and he has served as a reviewer for prominent scientific publications. Additionally, he is the founder of The Saudi Scientific Society for the Application of Artificial Intelligence in Drug Discovery and Health Research, illustrating his commitment to integrating emerging technologies in healthcare.
His contributions extend to community service and awareness. Dr. Alrohaimi established the National Drug and Poisoning Center and initiated educational programs such as the National Poisoning Week, addressing critical public health challenges. His dedication to advancing healthcare education is evident in his active involvement in training programs, regulatory frameworks, and post- marketing drug studies.
In addition to his scientific expertise, Dr. Alrohaimi is recognized for his leadership and strategic vision. His work bridges the domains of academia, industry, and public policy, contributing significantly to the Kingdom’s transformation into a global leader in science, healthcare, and innovation.
Proficient in Arabic and English, Dr. Alrohaimi continues to inspire through his dedication to education, research, and national progress. His legacy is a testament to the power of integrating knowledge, leadership, and a clear vision for a brighter future.
Dr. Abdulmohsen H. Alrohaimi’s research interests include pharmacogenetics, nanomedicine-based drug delivery, stem cell techniques, and biotechnology. He is also focused on clinical trials infrastructure, post-marketing drug studies, and the application of artificial intelligence in drug discovery and healthcare.
AI’s Breakthroughs in HIV Eradication and Precision Oncology
Artificial intelligence (AI) is revolutionizing drug innovation, offering unprecedented solutions to longstanding challenges in global healthcare. This abstract explores two transformative frontiers: HIV eradication and precision oncology, where AI bridges the gap between scientific ambition and clinical impact. In the fight against HIV, AI-driven platforms like VAXX Research Inc.’s CureiTec™ are accelerating preclinical timelines by 50%, leveraging predictive algorithms and replicon mRNA technology to design vaccines that target viral reservoirs with unprecedented precision. By integrating multimodal data—from genomics to immune cell engineering—these platforms reduce development costs while enhancing therapeutic efficacy, bringing us closer to a functional cure by 2035. Simultaneously, in oncology, AI is redefining personalized care. Platforms such as PrecisionMed AI analyze patient-specific factors (genetic profiles, lifestyle, and clinical history) to optimize chemotherapy regimens, reducing severe side effects by 73% and improving survival rates through tailored treatment plans. These innovations highlight AI’s ability to transform “one-size-fits-all” approaches into dynamic, patient-centric solutions.
However, the rapid adoption of AI in drug development necessitates robust intellectual property (IP) frameworks. Case studies from HIV and oncology demonstrate how safeguarding proprietary algorithms, datasets, and multimodal platforms is critical to sustaining innovation while fostering ethical collaboration. For instance, VAXX’s patent-pending AI models for replicon design and PrecisionMed’s encrypted EHR-integrated systems illustrate strategies to balance open science with commercial viability. As AI reshapes drug discovery, stakeholders must prioritize adaptive regulatory policies and cross-sector partnerships to scale breakthroughs equitably. This abstract underscores AI’s dual role as both a disruptor and enabler, offering actionable insights for researchers, policymakers, and clinicians committed to advancing a future where HIV is eradicated, cancer is managed with precision, and innovation thrives within secure, ethical boundaries.